Spots Global Cancer Trial Database for Study of Panitumumab in the Treatment of Carcinoid Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Panitumumab in the Treatment of Carcinoid Syndrome
Official Title: Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome
Study ID: NCT01172717
Conditions
Interventions
Study Description
Brief Summary: The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Boston Medical Center, Boston, Massachusetts, United States
Lahey Clinic, Burlington, Massachusetts, United States
Contact Details
Name: Kevan Hartshorn, MD
Affiliation: Boston Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
